Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily vs Standard Tigecycline in Critically Ill Patients
NCT07258225Phase 4Active, not recruiting
- Sponsor
- PLA Air Force Characteristic Medical Center
- Start
- Apr 2024
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4 trial of tigecycline in Infection (2 arms), sponsored by PLA Air Force Characteristic Medical Center. Primary endpoints: Treatment outcomes (clinical response) at 28 days and Safety of tigecycline regimens at 28 days. Started Apr 2024; status: active, not recruiting.
02
Drugs
tigecycline
03
Conditions
Infection
Beyond the preview
Go deeper on NCT07258225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258225.